Chemotherapy-induced toxicities and treatment efficacy in advanced esophageal cancer treated with neoadjuvant chemotherapy followed by surgery

Esophagus

Volumn 8, Issue 2, 2011, Pages 81-87

  Motoori, Masaaki ^a   Yano, Masahiko ^a   Yasuda, Takushi ^b   Miyata, Hiroshi ^c   Peng, Yingfeng ^b   Yamasaki, Makoto ^c   Shiraishi, Osamu ^b   Masuzawa, Toru ^c   Tanaka, Koji ^a   Ishikawa, Osamu ^a   Shiozaki, Hitoshi ^b   Doki, Yuichiro ^c  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Adverse events; Esophageal cancer; Neoadjuvant chemotherapy; Treatment efficacy

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANASTOMOSIS LEAKAGE; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HUMAN; KIDNEY DYSFUNCTION; LEUKOPENIA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RECURRENT LARYNGEAL NERVE PALSY; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BLEEDING; TUMOR VOLUME;

EID: 80051795703     PISSN: 16129059     EISSN: 16129067     Source Type: Journal    
DOI: 10.1007/s10388-011-0267-7     Document Type: Article

References (26)

1. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg. 1994;220:364-72.
2. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002; 359:1727-33.
3. Igaki H, Kato H, Ando N, et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol 2008;26(suppl): abstract 4510.
4. Ando N, Iizuka T, Ide H, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 2003;21:4592-6. (Pubitemid 46594032)
5. Kishi K, Doki Y, Yano M, et al. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. Clin Cancer Res. 2003;9:4368-75. (Pubitemid 37248393)
6. Luthra R, Wu TT, Luthra MG, et al. Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol. 2006; 24:259-67. (Pubitemid 46628468)
7. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007;8:797-805. (Pubitemid 47308659)
8. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol. 2007;25:3205-9. (Pubitemid 47333732)
9. Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6:669-77. (Pubitemid 41222757)
10. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer. 1997;75:301-5. (Pubitemid 27019578)
11. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in nodepositive breast cancer treated with adjuvant CMF. Br J Cancer. 1999;80:1763-6. (Pubitemid 29389629)
12. Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer. 2003;89:1837-42. (Pubitemid 37533256)
13. Sobin LH, Wittekind CH. TNM classification of malignant tumors. 6th edn. New York: Wiley-Liss; 2002.
14. Akita H, Doki Y, Miyata H, et al. Clinical significance of the second cycle response to cisplatin-based chemotherapy as preoperative treatment for esophageal squamous cell carcinoma. J Surg Oncol. 2006;93:401-9.
15. Matsuyama J, Doki Y, Yasuda T, et al. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery (St. Louis). 2007;141:570-80. (Pubitemid 46616931)
16. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:979-84.
17. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer (Phila). 2001;91:2165-74. (Pubitemid 32476382)
18. Schuell B, Gruenberger T, Kornek GV, et al. Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Br J Cancer. 2005;93:744-8. (Pubitemid 41486432)
19. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M, et al. Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. Br J Cancer. 2007;97:37-42. (Pubitemid 47012089)
20. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer. 1989;59:287-90. (Pubitemid 19072735)
21. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer (Phila). 1996;77:441-51. (Pubitemid 26047564)
22. Di Paolo A, Lencioni M, Amatori F, et al. 5-Fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res. 2008;14:2749-55.
23. Gusella M, Frigo AC, Bolzonella C, et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer. 2009;100:1549-57.
24. Vokes EE, Mick R, Kies MS, et al. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol. 1996;14:1663-71. (Pubitemid 26139706)
25. Schmidt H, Suciu S, Punt CJ, et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on cancer stage IV melanoma: results of the EORTC 18951 biochemotherapy trial. J Clin Oncol. 2007;25:1562-9. (Pubitemid 46733083)
26. Kasuga I,Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer (Phila). 2001;92:2399-405. (Pubitemid 33029085)